Literature DB >> 12940649

Diffuse neuroaxonal involvement in mucolipidosis IV as assessed by proton magnetic resonance spectroscopic imaging.

Simona Bonavita1, Anette Virta, Neal Jeffries, Ehud Goldin, Gioacchino Tedeschi, Raphael Schiffmann.   

Abstract

Mucolipidosis IV is an autosomal recessive disorder caused by mutations in MCOLN1, which codes for mucolipin, a transient receptor potential protein. In order to investigate brain metabolic abnormalities in mucolipidosis IV, we studied 14 patients (11 children, 3 adults) by proton magnetic resonance spectroscopic imaging. The ratios of N-acetylaspartate/ creatine-phosphocreatine and N-acetylaspartate/choline-containing compounds in patients with mucolipidosis IV were significantly reduced in all regions of interest except the parietal gray matter and thalamus. The ratios of choline-containing compounds/creatine-phosphocreatine was not significantly reduced in patients compared with controls. The ratio of N-acetylaspartate/creatine-phosphocreatine were significantly lower (P = .005) in the more neurologically impaired patients compared with the least impaired. For every region of interest, except for parietal gray matter, the ratio of N-acetylaspartate/creatine-phosphocreatine was lower in the more motorically impaired patient group. There was no difference for the ratio of N-acetylaspartate/creatine-phosphocreatine between younger and older patients. These findings suggest that mucolipidosis IV is largely a static developmental encephalopathy associated with diffuse neuronal and axonal damage or dysfunction. Mucolipin deficiency impairs motor more than sensory central nervous system pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12940649     DOI: 10.1177/08830738030180070701

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  13 in total

1.  Novel degenerative and developmental defects in a zebrafish model of mucolipidosis type IV.

Authors:  Huiqing Li; Wuhong Pei; Sivia Vergarajauregui; Patricia M Zerfas; Nina Raben; Shawn M Burgess; Rosa Puertollano
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

2.  Quantitative neuroimaging in mucolipidosis type IV.

Authors:  Raphael Schiffmann; Joan Mayfield; Caren Swift; Igor Nestrasil
Journal:  Mol Genet Metab       Date:  2013-11-21       Impact factor: 4.797

Review 3.  Mucolipidosis type IV: an update.

Authors:  Kazuyo Wakabayashi; Ann Marie Gustafson; Ellen Sidransky; Ehud Goldin
Journal:  Mol Genet Metab       Date:  2011-06-16       Impact factor: 4.797

4.  Autophagy, mitochondria and cell death in lysosomal storage diseases.

Authors:  Kirill Kiselyov; John J Jennigs; Youssef Rbaibi; Charleen T Chu
Journal:  Autophagy       Date:  2007-05-23       Impact factor: 16.016

Review 5.  Autophagy in lysosomal storage disorders.

Authors:  Andrew P Lieberman; Rosa Puertollano; Nina Raben; Susan Slaugenhaupt; Steven U Walkley; Andrea Ballabio
Journal:  Autophagy       Date:  2012-05-01       Impact factor: 16.016

Review 6.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

7.  Fingolimod phosphate inhibits astrocyte inflammatory activity in mucolipidosis IV.

Authors:  Laura D Weinstock; Amanda M Furness; Shawn S Herron; Sierra S Smith; Sitara B Sankar; Samantha G DeRosa; Dadi Gao; Molly E Mepyans; Anna Scotto Rosato; Diego L Medina; Ayelet Vardi; Natalia S Ferreira; Soo Min Cho; Anthony H Futerman; Susan A Slaugenhaupt; Levi B Wood; Yulia Grishchuk
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

8.  Neuropathology of the Mcoln1(-/-) knockout mouse model of mucolipidosis type IV.

Authors:  Matthew C Micsenyi; Kostantin Dobrenis; Gloria Stephney; James Pickel; Marie T Vanier; Susan A Slaugenhaupt; Steven U Walkley
Journal:  J Neuropathol Exp Neurol       Date:  2009-02       Impact factor: 3.685

9.  Progress in elucidating pathophysiology of mucolipidosis IV.

Authors:  Albert Misko; Levi Wood; Kirill Kiselyov; Susan Slaugenhaupt; Yulia Grishchuk
Journal:  Neurosci Lett       Date:  2021-05-11       Impact factor: 3.197

10.  Behavioral deficits, early gliosis, dysmyelination and synaptic dysfunction in a mouse model of mucolipidosis IV.

Authors:  Yulia Grishchuk; Sarmi Sri; Nikita Rudinskiy; Weiyuan Ma; Katherine G Stember; Matthew W Cottle; Ellen Sapp; Marian Difiglia; Alona Muzikansky; Rebecca A Betensky; Andrew M S Wong; Brian J Bacskai; Bradley T Hyman; Raymond J Kelleher; Jonathan D Cooper; Susan A Slaugenhaupt
Journal:  Acta Neuropathol Commun       Date:  2014-09-09       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.